Literature DB >> 30040997

Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems.

Wenqi Wu1, Hiroshi Ueda2, Korbinian Löbmann1, Thomas Rades1, Holger Grohganz3.   

Abstract

Co-amorphous drug delivery systems are attracting increasing attention in the pharmaceutical field, due to their promising potential to improve the solubility and bioavailability of poorly water-soluble drugs. In this study, three organic acids, namely benzoic acid, malic acid and citric acid, were investigated as co-formers for the weakly basic drug carvedilol. It was hypothesised that the mono-, di- and triprotic nature of the organic acids could result in co-amorphous salt formation with carvedilol at the respective stoichiometric molar ratios, leading to different physicochemical properties of the co-amorphous samples. The carvedilol-organic acid samples were spray dried at molar ratios from 1:4 to 4:1 and amorphous products were obtained for all mixtures except for carvedilol-benzoic acid at a molar ratio of 1:4. A positive deviation of the glass transition temperature compared to the Gordon-Taylor equation was seen for all co-amorphous samples. Salt formation was confirmed by FTIR, but interestingly complete salt formation did not simply follow the molar ratio of the number of basic and acidic groups, most likely due to steric hindrance. As more than one molecule of carvedilol was found to be involved in most co-amorphous systems with the organic acids, this approach allows for a higher "drug loading" compared to other co-formers that usually form co-amorphous systems at a 1:1 M ratio. In addition, the large number of available organic acids offers various options for selecting co-formers.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30040997     DOI: 10.1016/j.ejpb.2018.07.016

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

Review 1.  Co-amorphous Drug Delivery Systems: a Review of Physical Stability, In Vitro and In Vivo Performance.

Authors:  Qin Shi; Yanan Wang; Sakib M Moinuddin; Xiaodong Feng; Fakhrul Ahsan
Journal:  AAPS PharmSciTech       Date:  2022-09-19       Impact factor: 4.026

2.  A Multivariate Approach for the Determination of the Optimal Mixing Ratio of the Non-Strong Interacting Co-Amorphous System Carvedilol-Tryptophan.

Authors:  Rong Di; Jingwen Liu; Holger Grohganz; Thomas Rades
Journal:  Molecules       Date:  2021-02-04       Impact factor: 4.411

3.  Computed Tomographic Image Processing and Reconstruction in the Diagnosis of Rare Osteochondroma.

Authors:  Ting Zhao; Hongyan Zhao
Journal:  Comput Math Methods Med       Date:  2021-08-14       Impact factor: 2.238

4.  BX795-Organic Acid Coevaporates: Evaluation of Solid-State Characteristics, In Vitro Cytocompatibility and In Vitro Activity against HSV-1 and HSV-2.

Authors:  Yogesh Sutar; Tejabhiram Yadavalli; Sagar Kumar Paul; Sudipta Mallick; Raghuram Koganti; Harsh Chauhan; Abhijit A Date; Deepak Shukla
Journal:  Pharmaceutics       Date:  2021-11-12       Impact factor: 6.321

5.  Prediction and Preparation of Coamorphous Phases of a Bislactam.

Authors:  Luke I Chambers; Osama M Musa; Jonathan W Steed
Journal:  Mol Pharm       Date:  2022-06-22       Impact factor: 5.364

6.  Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends.

Authors:  Nuno F da Costa; Rolf Daniels; Ana I Fernandes; João F Pinto
Journal:  Pharmaceutics       Date:  2022-07-23       Impact factor: 6.525

Review 7.  Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies.

Authors:  Jingwen Liu; Holger Grohganz; Korbinian Löbmann; Thomas Rades; Nele-Johanna Hempel
Journal:  Pharmaceutics       Date:  2021-03-15       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.